Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact

Loading news article.

Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact | WAPE

Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact

Article summary

Related companies

Comments —